TG Therapeutics TGTX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's total current liabilities?
- TG Therapeutics (TGTX) reported total current liabilities of $187.11M in Q1 2026.
- How has TG Therapeutics's total current liabilities changed year-over-year?
- TG Therapeutics's total current liabilities increased by 16.8% year-over-year, from $160.21M to $187.11M.
- What is the long-term trend for TG Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), TG Therapeutics's total current liabilities has grown at a 11.9% compound annual growth rate (CAGR), from $87.55M to $153.76M.
- What does total current liabilities mean?
- The total amount of debt and other obligations the company must pay within one year.
- How do you interpret total current liabilities?
- A lower ratio relative to current assets is generally preferred, as it indicates a stronger ability to cover short-term obligations.
- How does total current liabilities compare across companies?
- Investors compare this against current assets to calculate the current ratio, a standard benchmark for short-term financial health.